ESR1 and breast cancer: Rigorous preclinical studies will be needed to develop clear criteria for “low levels” and to determine whether our results can be translated to a clinical setting, and whether this combination therapy can ultimately become a novel therapeutic choice for ERα+ BC patients with reduced SPRED2 expression levels.